SolasCure enrols first patient in a next phase II clinical trial to advance Aurase Wound Gel

Post author:admin
Post published: March 17, 2025
Post category:uncategorized

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Ukrainian researcher develops digital tool for detecting autism and developmental delay in kids

KFF Health News’ ‘What the Health?’: Supreme Court upholds bans on gender-affirming care

CHAPPER healthcare, AscellaHealth’s global pharmaceutical distributor, assumes presidency of EUROPACCESS, enhancing access to innovative medicines

Helpful Links

Subscribe To Us